Complexity of medication use in the veterans affairs healthcare system: Part II. Antidepressant use among younger and older outpatients

Journal of Psychiatric Practice

Volumn 11, Issue 1, 2005, Pages 16-26

  Silkey, Beryl ^a   Preskorn, Sheldon H ^b   Golbeck, Amanda ^b   Shah, Rozina ^c   Neff, Melissa ^d   Jones, Teresa L ^b   Choi, Joe ^c  

^a Via Christi Research Institute ^*  (United States)

^b UNIVERSITY OF KANSAS SCHOOL OF MEDICINE WICHITA   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d Vet Integrated Service Network 15   (United States)

Author keywords

Antidepressants; Drug interactions; Multiple medication use; Polypharmacy; Prescribing practices; Veterans Affairs

Indexed keywords

ACETYLSALICYLIC ACID; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; FLUOXETINE; IBUPROFEN; LEVOTHYROXINE; LISINOPRIL; NAPROXEN; PAROXETINE; RANITIDINE; SERTRALINE;

ADULT; AGE DETERMINATION; AGED; ARTICLE; DRUG SAFETY; DRUG USE; ETHNOLOGY; FEMALE; GENDER; HEALTH CARE SYSTEM; HUMAN; MALE; OUTCOMES RESEARCH; OUTPATIENT; POLYPHARMACY; PRESCRIPTION; PREVALENCE; PSYCHOTHERAPY; RISK ASSESSMENT; SOLDIER;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIDEPRESSIVE AGENTS; DEMOGRAPHY; DEPRESSIVE DISORDER; FEMALE; HUMANS; MALE; MENTAL HEALTH SERVICES; MIDDLE AGED; POLYPHARMACY; UNITED STATES; UNITED STATES DEPARTMENT OF VETERANS AFFAIRS;

EID: 12844283992     PISSN: 15274160     EISSN: None     Source Type: Journal    
DOI: 10.1097/00131746-200501000-00003     Document Type: Article

References (71)

1. Healthy People 2010: National health promotion and disease prevention objectives. Washington, DC: U.S. Department of Health and Human Services; 2001. Also available at http: //web.health.gov/healthypeople/document. Accessed March 3, 2004.
2. Nolan L, O'Malley K. Prescribing for the elderly. Part I: Sensitivity of the elderly to drug reactions. J Am Geriatr Soc 1988;36:142-9.
3. Fattinger K, Roos M, Vergeres P, et al. Epidemiology of drug exposure and adverse drug reactions in two Swiss departments of internal medicine. Br J Clin Pharmacol 2000;49:158-67.
4. Cooper JW. Adverse drug-reaction-related hospitalizations of nursing home facility patients: A 4-year study. South Med J 1999;92:485-90.
5. Koechler JA, Abramowitz PW, Swim SE, et al. Indicators for the selection of ambulatory patients who warrant pharmacist monitoring. Am J Hosp Pharm 1989;46:729-32.
6. Hanlon JT, Fillenbaum GG, Schmader KE, et al. Inappropriate drug use among community-dwelling elderly. Pharmacotherapy 2000;20:575-82.
7. Colley CA, Lucas LM. Polypharmacy: The cure becomes the disease. J Gen Intern Med 1993;8:278-83.
8. Bates DW, Miller EB, Cullen DJ, et al. Patient risk factors for adverse drug events in hospitalized patients. Arch Int Med 1999;159:2553-60.
9. Gurwitz JH, Field TS, Harrold LR, et al. Incidence and preventability of adverse drug events among older persons in the ambulatory setting. JAMA. 2003;289:1107-15.
10. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: A meta-analysis of prospective studies. JAMA 1998;279:1200-5.
11. Beyth RJ, Shorr RI. Epidemiology of adverse drug reactions in the elderly by drug class. Drugs and Aging 1999;14:231-9.
12. Cullen DJ, Sweitzer BJ, Bates DW, et al. Preventable adverse drug events in hospitalized patients: A comparative study of intensive care units and general care units. Crit Care Med 1997;25:1289-97.
13. Hanlon JT, Schmader KE, Koronkowski MJ, et al. Adverse drug events in high risk older outpatients. J Am Geriatr Soc 1997;45:945-8.
14. Field TS, Gurwitz JH, Avorn J, et al. Risk factors for adverse drug events among nursing home residents. Arch Intern Med 2001;161:1629-34.
15. Barat I, Andreasen F, Damsgaard EMS. The consumption of drugs by 75-year-old individuals living in their homes. Eur J Clin Pharmacol. 2000;56:501-509.
16. Bates DW, Spell N, Cullen DJ, et al. The costs of adverse drug events in hospitalized patients. JAMA 1997;277:307-11.
17. Leape LL, Bates DW, Cullen DJ, et al. Systems analysis of adverse drug events. JAMA 1995;274:35-43.
18. Routledge PA, O'Mahony MS, Woodhouse KW. Adverse drug reactions in elderly patients. Br J Clin Pharmacol 2004;57:121-6.
19. Halkin H, Katzir I, Kurman I, et al. Preventing drug interactions by online prescription screening in community pharmacies and medical practices. Clin Pharmacol Ther 2001;69:260-5.
20. Raschke RA, Gollihare B, Wunderlich TA, et al. A computer alert system to prevent injury from adverse drug events: Development and evaluation in a community teaching hospital. JAMA 1996;280:1317-20.
21. Samsa GP, Hanlon JT, Schmader KE, et al. A summated score for the medication appropriateness index: Development and assessment of clinimetric properties including content validity. J Clin Epidemiol 1994;47:891-6.
22. Schmader K, Hanlon JT, Weinberger M, et al. Appropriateness of medication prescribing in ambulatory elderly patients. J Am Geriatr Soc 1994;42:1241-7.
23. Fick DM, Cooper JW, Wade WE, et al. Updating the Beers criteria for potentially inappropriate medication use in older adults: Results of a US consensus panel of experts. Arch Intern Med 2003;163:2716-24.
24. Carter BL, Malone DC, Valuck RJ, et al. The IMPROVE study: Background and study design. Am J Health-Syst Pharm 1998;55:62-7.
25. Hamdy RC, Moore SW, Whalen K, et al. Reducing polypharmacy in extended care. South Med J 1995;88:534-8.
26. Jameson JP, VanNoord GR. Pharmacotherapy consultation on polypharmacy patients in ambulatory care. Ann Pharmacother 2001;35:835-40.
27. Hanlon JT, Weinberger M, Samsa GP, et al. A randomized, controlled trial of a clinical pharmacist intervention to improve inappropriate prescribing in elderly outpatients with polypharmacy. Am J Med 1996;100:428-37.
28. McMullin ST, Reichley RM, Kahn MG, et al. Automated system for identifying potential dosage problems in a large university hospital. Am J Health Syst Pharm 1997;54:545-9.
29. Preskorn SH, Silkey B, Shah R, et al. Complexity of outpatient medication use in the Veterans Affairs healthcare system: Part I. Outpatient use in relation to age and number of prescribers. J Psychiatr Pract 2005;11:5-15.
30. Kaufman DW, Kelly JP, Rosenberg L, et al. Recent patterns of medication use in the ambulatory adult population of the United States: The Slone Survey. JAMA 2002;287:337-44.
31. Bjerrum L, Sogaard J, Hallas J, et al. Polypharmacy: Correlations with sex, age, and drug regimen: A prescription database study. Eur J Clin Pharmacol 1998;54:197-202.
32. Bjerrum L, Rosholm JU, Hallas J, et al. Methods for estimating the occurrence of polypharmacy by means of a prescription database. Eur J Clin Pharmacol 1997;53:7-11.
33. Rosholm JU, Bjerrum L, Hallas J, et al. Polypharmacy and the risk of drug-drug interactions among Danish elderly: A prescription database study. Dan Med Bull 1998;45:210-3.
34. Atkin PA, Veitch PC, Veitch EM, et al. The epidemiology of serious adverse drug reactions among the elderly. Drugs and Aging 1999;14:141-52.
35. Ebly EM, Hogan DB, Fung TS. Potential adverse outcomes of psychotropic and narcotic use in Canadian seniors. J Clin Epidemiol 1997;50:857-63.
36. Lawlor DA, Patel R, Ebrahim S. Association between falls in elderly women and chronic diseases and drug use: Cross sectional study. BMJ 2003;327:712-7.
37. Moore AR, O'Keefe ST. Drug-induced cognitive impairment in the elderly. Drugs and Aging 1999;15:15-28.
38. Weiner DK, Hanlon JT, Studenski SA. Effects of central nervous system polypharmacy on falls liability in community-dwelling elderly. Gerontology 1998;44:217-21.
39. Thapa PB, Gideon P, Cost TW, et al. Antidepressants and the risk of falls among nursing home residents. N Engl J Med 1998;339:875-82.
40. Leipzig RM, Cumming RG, Tinetti ME. Drugs and falls in older people: A systematic review and meta-analysis. I. Psychotropic drugs. J Am Geriatr Soc 1999;47:40-50.
41. Lawson DH. Life threatening drug reactions amongst medical in-patients. Scot Med J 1979;24:127-30.
42. Preskorn SH, Jerkovich GS. Central nervous system toxicity of tricyclic antidepressants: Phenomenology, course, risk factors, and role of therapeutic drug monitoring. J Clin Psychopharmacol. 1990;10:88-95.
43. Muijen M, Silverstone T. A comparative hospital survey of psychotropic drug prescribing. Br J Psychiatry 1987;150:501-4.
44. Willcox SM, Himmelstein DU, Woolhandler S. Inappropriate drug prescribing for the community-dwelling elderly. JAMA 1994;272:292-6.
45. Pincus HA, Tanielian TL, Marcus SC, et al. Prescribing trends in psychotropic medications: Primary care, psychiatry, and other medical specialties. JAMA 1998;279:526-31.
46. Olfson M, Marcus SC, Pincus HA, et al. Antidepressant prescribing practices of outpatient psychiatrists. Arch Gen Psychiatry 1998;55:310-6.
47. Olfson M, Marcus SC, Druss B, et al. National trends in the outpatient treatment of depression. JAMA 2002;287:203-9.
48. McManus P, Mant A, Mitchell PB, et al. Recent trends in the use of antidepressant drugs in Australia, 1990-1998. Med J Aust 2000;173:458-61.
49. Roberts E, Norris P. Growth and change in the prescribing of anti-depressants in New Zealand, 1993-1997. NZ Med J 2001;114:25-7.
50. Snedecor GW, Cochran WG. Statistical methods. Ames, IA: Iowa State University Press; 1980.
51. Fleiss JL. Statistical methods for rates and proportions. New York: John Wiley and Sons; 1973.
52. Coulehan JL, Schulberg HC, Block MR, et al. Depressive symptomatology and medical co-morbidity in a primary care setting. Int J Psychiatry Med 1990;20:335-47.
53. Spollen JJ III, Gutman D. The interaction of depression and medical illness: Depression and comorbid cardiovascular disease. Medscape. www.medscape.com/viewarticle/457165.
54. Cohen-Cole SA, Kaufman KG. Major depression in physical illness: Diagnosis, prevalence, and antidepressant treatment (a ten year review: 1982-1992). Depression 1993;1:181-204.
55. Gagnon LM, Patten SB Major depression and its association with long-term medical conditions. Can J Psychiatry 2002;47:149-52.
56. Haug TT, Mykletun A, Dahl AA. Are anxiety and depression related to gastrointestinal symptoms in the general population? Scan J Gastroenterol 2002;3:294-8.
57. Anderson RJ, Freedland KE, Clouse RE, et al. The prevalence of comorbid depression in adults with diabetes: A meta-analysis. Diab Care 2001;24:1069-78.
58. Lacro JP, Jeste DV. Physical comorbidity and polypharmacy in older psychiatric patients. Biol Psychiatry 1994;36:146-52.
59. Wells KB, Rogers W, Burnam A, et al. How the medical comorbidity of depressed patients differs across health care settings: Results from the Medical Outcomes Study. Am J Psychiatr 1991;148:1688-96.
60. Blazer DG, Kessler RC, McGonagle KA, et al. The prevalence and distribution of major depression in the national community sample; The National Comorbidity Survey. Am J Psychiatry 1994;151:979-86.
61. Carney RM, Rich MW, teVelde A, et al. Major depressive disorder in coronary artery disease. Am J Cardiol 1987;60:1273-5.
62. Forester AW, Lipsey JR, Teitelbaum ML, et al. Depression following myocardial infarction. Int J Psychiatry Med 1992;22:33-46.
63. Gonzalez MB, Snyderman TB, Colket JT, et al. Depression in patients with coronary artery disease. Depression 1996;4:57-62.
64. Weissman MM, Bland RC, Canino GJ, et al. Cross-national epidemiology of major depression and bipolar disorder. JAMA 1996;276:293-9.
65. Wells KB, Stewart A, Hays RD, et al. The functioning and well-being of depressed patients: Results from the Medical Outcomes Study. JAMA 1989;262:914-9.
66. Kazis LE, Ren XS, Lee A, et al. Health status in VA patients: Results from the Veterans Health Study. Am J Med Qual 1999;14:28-38.
67. Wolinsky FD, Coo RM, Mosely RR, et al. Veterans and nonveterans use of health services: A comparative analysis. Med Care 1985;23:1358-71.
68. Sloan KL, Fishman PA, Malkin JD. Comparing VA to the Group Health Population on the chronic disease score categories. Presentation, 2000 HSR&D Annual Meetings.
69. Ogden JE, Muniz A, Patterson AA, et al. Pharmaceutical services in the Department of Veterans Affairs. Am J Health Syst Pharm 1997;54:761-75.
70. Miller DR, Skinner KM, Kazis LE. Study design and sampling in the Veterans Health Study. J Ambul Care Manage 2004;27:166-79.
71. Kressin N. Challenges in conducting research on racial variations in health care. Washington, DC: Workshop held at the VA Health Services Research and Development Meetings, 2000.